Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Cutaneous adverse reactions following initiation of vanzacaftor/tezacaftor/deutivacaftor in CFTR-modulator-naïve subjects: a case series.

Created on 27 Oct 2026

Authors

V Terlizzi, C Cimbalo, S Del Vespa, R Paggi, T Manciulli, S Bresci

Published in

Respiratory medicine. Pages 109248. Oct 26, 2026. Epub Oct 26, 2026.

Abstract

The introduction of CFTR modulators has revolutionized the treatment of cystic fibrosis (CF). Recently, the triple combination vanzacaftor/tezacaftor/deutivacaftor (VTD) has been approved, expanding the population of people with CF (pwCF) eligible for treatment. Since the introduction of CFTR modulators, post-marketing surveillance of drug-related adverse events (AEs) has become increasingly relevant. Here, we report the first real-world data on the prevalence, clinical presentation, and management of cutaneous AEs associated with VTD in pwCF followed in the Tuscany region, Italy.

PMID:
42933675
Bibliographic data and abstract were imported from PubMed on 27 Oct 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 15
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement